Hyaluronic acid improves “pleasantness” and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis

[1]  V. McDonald,et al.  Nebulised hypertonic saline for cystic fibrosis. , 2009, The Cochrane database of systematic reviews.

[2]  Karen A Robinson,et al.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.

[3]  F. Ratjen,et al.  Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis , 2007, Pediatric pulmonology.

[4]  R. Boucher,et al.  Evidence for airway surface dehydration as the initiating event in CF airway disease , 2007, Journal of internal medicine.

[5]  M. Elkins,et al.  Inhaled hypertonic saline as a therapy for cystic fibrosis , 2006, Current opinion in pulmonary medicine.

[6]  P. Sterk,et al.  Inhaled hyaluronic acid against exercise-induced bronchoconstriction in asthma. , 2006, Pulmonary pharmacology & therapeutics.

[7]  L. Allegra,et al.  Aerosolised hyaluronic acid prevents exercise-induced bronchoconstriction, suggesting novel hypotheses on the correction of matrix defects in asthma. , 2006, Pulmonary pharmacology & therapeutics.

[8]  Mark R Elkins,et al.  A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. , 2006, The New England journal of medicine.

[9]  M. Knowles,et al.  Mucus clearance and lung function in cystic fibrosis with hypertonic saline. , 2006, The New England journal of medicine.

[10]  W. Abraham,et al.  Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. , 2003, Pulmonary pharmacology & therapeutics.

[11]  G. Turino,et al.  Hyaluronan in respiratory injury and repair. , 2003, American journal of respiratory and critical care medicine.

[12]  V. McDonald,et al.  Nebulised hypertonic saline for cystic fibrosis. , 2003, The Cochrane database of systematic reviews.

[13]  T. Maurer,et al.  A comparison of Likert scale and traditional measures of self-efficacy. , 1998 .

[14]  L. Wong,et al.  Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. , 1997, The Journal of pediatrics.

[15]  J. Fraser,et al.  Hyaluronan: its nature, distribution, functions and turnover , 1997, Journal of internal medicine.

[16]  R. Dahl,et al.  Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. , 1996, American journal of respiratory and critical care medicine.

[17]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[18]  C. Stevens,et al.  Aquaporin 4 and glymphatic flow have central roles in brain fluid homeostasis , 2021, Nature Reviews Neuroscience.

[19]  F. Collins,et al.  Cystic fibrosis: molecular biology and therapeutic implications. , 1992, Science.

[20]  R. Hällgren,et al.  Lung accumulation of hyaluronan parallels pulmonary edema in experimental alveolitis. , 1989, The American journal of physiology.

[21]  H. Muir,et al.  Hyaluronic acid in human articular cartilage. Age-related changes in content and size. , 1988, The Biochemical journal.

[22]  L. Rosenberg,et al.  An Overview of Proteoglycans in Physiology and Pathology , 1982 .

[23]  K. Schmid,et al.  The distribution of the glycosaminoglycans in the anatomic components of the lung and the changes in concentration of these macromolecules during development and aging. , 1982, Biochimica et biophysica acta.

[24]  R. Varma,et al.  Glycosaminoglycans and proteoglycans in physiological and pathological processes of body systems , 1982 .

[25]  E. Balazs,et al.  Chemistry and molecular biology of the intercellular matrix , 1970 .

[26]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[27]  B. Weissmann,et al.  STRUCTURE OF HYALURONIC ACID. THE GLUCURONIDIC LINKAGE , 1952 .